Login
$ZURA
$1.05 -$0.03 (2.72%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Sandeep Kulkarni Also a director
Chief Executive Officer and Director
44 Not stated Not stated Not reported
Kim Davis
Chief Operating Officer, Chief Legal Officer and Corporate Secretary
58 Since 2025
1 year
2022 $1,281,291
Gary Whale
Chief Technology Officer
52 Since 2023
3 years
2023 Not reported
Kiran Nistala
Chief Medical Officer and Head of Development
54 Since 2023
3 years
Not stated $1,022,568

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
7 of 7
stated in the proxy; 1 not stated
Average tenure
2.1 years
from year joined
CEO also chairs the board
No
Amit Munshi
Director Age On board Independent Committees Other public boards 2025 pay Source
Amit Munshi
58 2023
3 years
Independent
Audit Committee
Arcutis Inc. $121,131
Sandeep Kulkarni
44 2023
3 years
Not stated None stated None stated $97,681
Dan Becker
51 2025
1 year
Independent
Compensation Committee · Chair
None stated $73,448
Mark Eisner
60 2026
this year
Independent None stated None stated Not stated
Jennifer Jarrett
55 2023
3 years
Independent
Audit Committee
Syndax Pharmaceuticals, Inc. $92,581
Ajay Nirula
59 2026
this year
Independent None stated None stated Not stated
Steven Schoch
67 2023
3 years
Independent
Audit Committee · Chair
None stated $98,131
Parvinder Thiara
40 2022
4 years
Independent
Nominating and Governance Committee · Chair
None stated $21,846

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Kiran Nistala
Approximately $10,000
2024

Purchased 3,195 Class A ordinary shares in the April 2024 private placement at $3.13 per share

With the Company Open in proxy
Mountaineer Biosciences, Inc.
entity for which Michael Howell, our former Chief Scientific Officer, is the co-founder
Amount not stated
2024

Purchased 7,987 Class A ordinary shares in the April 2024 private placement at $3.13 per share

With the Company Open in proxy
Amount not stated
2024

Purchased 159,744 Class A ordinary shares in the April 2024 private placement at $3.13 per share

With the Company Open in proxy
Pegasus
entity of which Dr. Sidhu is the sole member
Amount not stated
2024

Purchased 1,186,901 Class A ordinary shares in the April 2024 private placement at $3.13 per share

With the Company Open in proxy
Entities affiliated with Venrock Healthcare Capital Partners
holder of more than 5% of capital stock
Amount not stated

Purchased 1,000,000 Class A ordinary shares and 500,000 pre-funded warrants in the February 2026 public offering

With Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. (underwriters) Open in proxy
AI Biotechnology LLC
holder of more than 5% of capital stock
Amount not stated

Purchased 2,000,000 Class A ordinary shares in the February 2026 public offering

With Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. (underwriters) Open in proxy
Suvretta Capital Management, LLC
holder of more than 5% of capital stock
Amount not stated

Purchased 3,500,000 Class A ordinary shares and 500,000 pre-funded warrants in the February 2026 public offering

With Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. (underwriters) Open in proxy
Great Point Partners, LLC
holder of more than 5% of capital stock
Amount not stated

Purchased 400,000 Class A ordinary shares and 2,500,000 pre-funded warrants in the February 2026 public offering

With Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. (underwriters) Open in proxy
Venrock Holders
Amount not stated
2024

Surrendered 4,000,000 Class A ordinary shares for no consideration in exchange for pre-funded warrants to purchase 4,000,000 Class A ordinary shares

With the Company Open in proxy
Venrock Holders
Amount not stated
2025

Agreed to surrender 3,500,000 Class A ordinary shares for no consideration in exchange for pre-funded warrants to purchase 3,500,000 Class A ordinary shares

With the Company Open in proxy
AI Biotechnology
Amount not stated
2025

Agreed to surrender 3,000,000 Class A ordinary shares for no consideration in exchange for pre-funded warrants to purchase 3,000,000 Class A ordinary shares

With the Company Open in proxy
Malina Munshi
daughter of Amit Munshi, the Company's independent chairman
Amount not stated
2024 and 2025

Employed by the Company as Senior Director, Corporate Planning & Operations, with compensation in 2024 and 2025

With the Company Open in proxy
Athanor Capital
Mr. Thiara is a director of Athanor Capital
Amount not stated

Letter agreement under which the Company issued 8,657,402 Class A ordinary shares, paid an upfront fee of $7.3 million, and agreed to a $25.0 million milestone payment and 2% Net Sales payments

With the Company, Z33 Bio Inc. and ZB17 Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support